Posted inHematology-Oncology news Oncology
Twice-Weekly All-Oral Ixazomib, Pomalidomide, and Dexamethasone Shows Durable Activity in Relapsed/Refractory Multiple Myeloma
A phase I/II study suggests twice-weekly ixazomib plus pomalidomide-dexamethasone is a feasible all-oral option in relapsed/refractory multiple myeloma, with a 65.8% response rate at the RP2D and manageable hematologic toxicity.